Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 9/20 | 0.40 |
| ▸ | OPRK1 | P41145 | 7/20 | 0.40 |
| ▸ | OPRD1 | P41143 | 6/20 | 0.40 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.40 |
| ▸ | SLC1A3 | P43003 | 2/20 | 0.39 |
| ▸ | SLC1A2 | P43004 | 2/20 | 0.39 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.35 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.35 |
| ▸ | GPR52 | Q9Y2T5 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7647619 | 0.87 | HCAR3 (0.41) | OPRM1OPRK1OPRD1HCAR3SLC1A3 | |
| SCHEMBL7643171 | 0.79 | CYP1A2 (0.44) | SLC1A3SLC1A2SLC1A1SLC6A2SLC6A3 | |
| SCHEMBL3380508 | 0.79 | CPA3 (0.46) | RAB9ASLC6A3 | |
| SCHEMBL7645014 | 0.73 | CHRNB2 (0.37) | HCAR3LTB4R | |
| SCHEMBL4314631 | 0.71 | SLC1A3 (0.53) | OPRM1OPRK1OPRD1SLC1A3SLC1A2 | |
| SCHEMBL3380552 | 0.68 | HDAC1 (0.49) | SLC6A3 | |
| SCHEMBL7647484 | 0.68 | KMT2A (0.38) | MEN1KMT2A | |
| SCHEMBL21548477 | 0.68 | SLC1A3 (0.56) | SLC1A3SLC1A2SLC1A1 | |
| SCHEMBL7284399 | 0.68 | SLC1A3 (0.56) | SLC1A3SLC1A2SLC1A1 | |
| SCHEMBL7654496 | 0.67 | EPOR (0.46) | MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020151503-A1 | Methods of cancer treatment using naaladase inhibitors | SLUSHER BARBARA S (US) | 2002-10-17 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020151503-A1 | Methods of cancer treatment using naaladase inhibitors | NAALAD2, DNPEP, ACP3 | OPRM1 4770/4885OPRK1 4661/4885OPRD1 4620/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.